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In an effort to identify novel candidate regula-
tors of adipogenesis, gene profiling of differen-
tiating 3T3-L1 preadipocytes was analyzed
using a novel algorithm. We report here the
characterization of xanthine oxidoreductase
(XOR) as a novel regulator of adipogenesis.
XOR lies downstream of C/EBPb and upstream
of PPARg, in the cascade of factors that control
adipogenesis, and it regulates PPARg activity.
In vitro, knockdown of XOR inhibits adipogene-
sis and PPARg activity while constitutive over-
expression increases activity of the PPARg
receptor in both adipocytes and preadipocytes.
In vivo, XOR / mice demonstrate 50% re-
duction in adipose mass versus wild-type
littermates while obese ob/ob mice exhibit
increased concentrations of XOR mRNA and
urate in the adipose tissue. We propose that
XOR is a novel regulator of adipogenesis and
of PPARg activity and essential for the regula-
tion of fat accretion. Our results identify XOR
as a potential therapeutic target for metabolic
abnormalities beyond hyperuricemia.
INTRODUCTION
Obesity, defined as an increased adipose tissue mass, is
an important public health problem in the developed world
and a growing problem in the developingworld.While sev-
eral of the molecular mechanisms that regulate adipocyte
development have been elucidated, there is a clear need
to more fully define the complex molecular processes
that control adipose tissue formation, in an effort tomanip-
ulate its accretion. In this report, we set out to identify
novel regulators expressed at a very early window during
the commitment of a preadipocyte to the adipogenic line-
age and with the potential to regulate the activity of proa-
dipogenic factors.Cell MThe conversion of a fibroblastic-like preadipocyte to
a mature adipocyte involves hormonal stimulators and
the induction of a whole network of transcription factors
that induce changes in gene expression and cell morphol-
ogy. At the top of this transcriptional hierarchy are the bzip
proteins C/EBPd, C/EBPb, C/EBPa, and the nuclear re-
ceptor PPARg (Cao et al., 1991; Yeh et al., 1995). These
transcription factors are induced in a sequential and tightly
regulated manner, and all are essential for normal adipo-
genesis. Among them, PPARg is considered to be the
master regulator since it is both necessary and sufficient
for adipose differentiation in vitro and in vivo (Evans
et al., 2004; Mueller et al., 2002; Rosen et al., 1999; Tonto-
noz et al., 1994). PPARg is a ligand-regulated nuclear-
hormone receptor that heterodimerizes with the retinoic
X receptor (RXR) (Tontonoz et al., 1994) and, upon ligand
binding, activates transcription of target genes. Liganded
PPARg and C/EBPb turn on C/EBPa expression (Zuo
et al., 2006), which then acts in concert with PPARg to
induce and maintain adipogenesis via the expression of
adipose-specific genes (Freytag et al., 1994; Wu et al.,
1999). However, it has been shown that many additional
factors regulate adipogenesis either by directly activating
adipogenic genes and/or regulating the synthesis of the
PPARg ligand.
In this report, we analyzed the gene-expression profiles
of 3T3-L1 cells to identify novel genes pivotal in the adipo-
genic process. In this analysis, emphasis was given to
genes whose expression was limited to the first 24 hr after
initiation of differentiation as a means for identifying earlier
regulators of the adipogenic process. Candidate genes
were ranked based on an algorithm modeling the com-
plexity of each gene-expression profile. Expression pro-
files were fit to a theoretical model of gene transcription
using nonlinear regression and ranked by their goodness
of fit. Candidates were further stratified by their expres-
sion within the desired time frame. The highest-scoring
candidate identified was the enzyme xanthine oxidore-
ductase (XOR). XOR catalyzes the catabolism of purines
such as xanthine and hypoxanthine to uric acid (Berry
and Hare, 2004; Harrison, 2002). XOR exists as a homo-
dimer with each subunit composed of iron-sulfur, FAD,
and molybdopterin binding domains and can be isolatedetabolism 5, 115–128, February 2007 ª2007 Elsevier Inc. 115
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Regulation of Adipogenesis by Xanthine Oxidasein two forms as either xanthine dehydrogenase (XDH) or
xanthine oxidase (XO). XDH possesses an additional
NAD+ binding site, and oxidation of substrates results in
electron transfer to NAD+. In XO, molecular oxygen is
used as an electron acceptor resulting in generation of re-
active oxygen species (ROS). Under certain conditions,
XDH can also function as an NADH oxidase to generate
ROS (Sanders et al., 1997). More recently, XOR has
been implicated in functions beyond purine metabolism
(Berry and Hare, 2004; Vorbach et al., 2002), such as the
generation of ROS and consequent tissue injury (Granger
et al., 1981; McCord, 1985), the endothelial dysfunction
seen in diabetes, in atherosclerosis, hypertension, and
congestive heart failure (Alderman and Aiyer, 2004;
Amado et al., 2005; Doehner et al., 2001; Landmesser
et al., 2002; Patetsios et al., 2001; White et al., 1996). In
addition, XOR constitutes a major component of the
milk-fat globule membrane, which is secreted in milk.
XOR colocalizes with the lipid binding protein adipophilin
on the milk-fat globule (McManaman et al., 2002), and in
one study global deletion of XOR in mice resulted in de-
fects in fat-droplet secretion (Vorbach et al., 2002). These
studies suggest a role for XOR in lipid-droplet export and
raise the question of whether this enzyme might oxidize or
reduce other substrates that function in the context of lipid
metabolism and adipogenesis.
Here we present our results that the enzyme XOR is
a novel regulator of the adipogenic process. By means
of knockdown and overexpression studies in vitro, we
show that XOR lies downstream of C/EBPb in the cascade
of factors that control adipogenesis, and upstream of
PPARg that regulates its activity. In vivo, increased XOR
expression and activity correlates with increased fat accu-
mulation and lack of XOR with reduced fat mass. Our ob-
servations are novel and link the activity of an enzyme to
the activity of an adipogenic transcription factor and
thus the adipogenic process. Our results also suggest
that adipose tissue XOR may be a contributing factor to
the hyperuricemia, atherogenic lipids, and oxidative stress
seen in obesity and identify XOR as a potential therapeutic
target for such metabolic abnormalities.
RESULTS
XOR Is a High-Scoring Candidate Regulator
of Adipogenesis
To identify genes temporally regulated during adipogene-
sis, we performed microarray analysis of 3T3-L1 preadi-
pocytes, at different time points during differentiation
(Soukas et al., 2001).
We developed a novel algorithm to identify temporally
regulated genes independent of fold change or expression
level for ranking genes. For each gene, the temporal
expression profile was fit to a model that defines gene ex-
pression as a linear combination of sigmoid functions (Fig-
ures S1A–S1C). Best-fit parameters were determined by
nonlinear regression. Subsequently, genes were ranked
by goodness of fit as determined by their R2 values. This
method of analysis was designed to identify genes with116 Cell Metabolism 5, 115–128, February 2007 ª2007 Elseviera profile of expression with few transcriptional events,
each well modeled by a sigmoid curve.
As an example, PPARg has a high R2 value of 0.996, and
it was expected that other genes with high R2 would be
good a priori candidates in the regulation of adipogenesis,
whereas genes with low R2 values, such as the ribosomal
protein Rps18 (R2 = 0.1) would be poor candidates. From
the set of top 40 genes selected by this algorithm, 72%
have been previously studied in adipocytes and 10% in
the setting of mitochondrial respiration, with the remaining
genes uncharacterized (Table S1).
Within the subset of genes with maximal expression at
an early time frame, the highest-ranking gene was XOR
(Figure 1A), with an R2 value of 0.999. Microarray analysis
of mouse tissues from our laboratory also confirmed high-
est expression of XOR in white adipose tissue (WAT),
followed by liver (L) and muscle (M). Expression was min-
imal in pancreas (P) and hypothalamus (H) (Figure 1B).
XOR mRNA and Activity Is Transiently Induced
during Adipocyte Differentiation In Vitro
We next analyzed XOR expression and activity in 3T3-L1
cells. XOR mRNA expression increased 8-fold during the
first 12 hr postinduction and subsequently declined to pre-
induction levels by day 3. This coincided with a rising
expression of aP2, a downstream target of PPARg and
a terminal marker of adipocyte differentiation (Figure 1C).
XOR enzymatic activity was assayed in 3T3-L1 cell ly-
sates that were incubated with the substrate xanthine in
the absence (assaying XO activity) or presence of NAD
(assaying both XO + XDH activity) in order to generate
uric acid. An HPLC assay for uric-acid levels was opti-
mized (Figures S2A–S2C). XDH activity was maximally in-
duced at 24 hr postinduction (Figure 1D), while XO activity
remained relatively unchanged.
XOR Levels Correlate with Adipose Mass,
and XOR / Mice Have Decreased Adiposity
We next assayed XOR expression in the white adipose tis-
sue of 6–8 week old male wild-type (WT), obese ob/ob
mice, and in ob/ob mice treated with leptin over a 12
day time period. XOR expression was elevated 2-fold in
ob/ob mice relative to WT, and treatment of ob/ob mice
with leptin reduced XOR mRNA to WT levels (Figure 2A).
Similarly, serum uric-acid levels were elevated in ob/ob
mice relative to WT and normalized by leptin treatment
(Figure 2B).
XOR null mice are phenotypically normal at birth but fail
to thrive and do not live beyond 6 weeks of age (Ohtsubo
et al., 2004; Vorbach et al., 2002). Analysis of adipose
stores from 2-week-old WT and XOR / mice showed
a 12% reduction in body weight in XOR / versus +/+
mice (Figure 2C), due to a 50% reduction in adipose con-
tent (Figure 2D). Serum analysis in XOR/mice showed
significantly decreased free fatty-acid concentrations,
while no significant differences were evident for glucose
and serum triglycerides (Figure 2E). These data suggest
that XOR may play a role in promoting in vivo adipogene-
sis, but it is also possible that the reduced adipose tissueInc.
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Regulation of Adipogenesis by Xanthine OxidaseFigure 1. XOR Is a High-Scoring Candi-
date for Regulation during Adipogenesis
(A) Microarray analysis of XOR (black line) and
aP2 (gray line) during 3T3-L1 differentiation.
(B) XOR expression was analyzed using tissue
microarray data. XOR expression is highest in
white adipose (WAT) and liver (L) and lower
in muscle (M), pancreas (P) and hypotha-
lamus (H).
(C) XOR expression during adipogenesis was
validated by quantitative RT-PCR. XOR ex-
pression is significantly induced between
6–12 hr postinduction, with a subsequent de-
cline (black bars). Decline of XOR expression
is coincident with rising aP2 levels (white
bars). Data are presented asmeans ± standard
error of the mean (SEM). N = 3–4.
(D) Cell lysates from differentiating 3T3-L1 cells
were incubated with xanthine in the absence
(XO activity, white bars) or presence of NAD
(XO + XDH activity) to generate uric acid.
XDH activity (black bars) was maximal at
24 hr postinduction. Data are presented as
means ± SEM. N = 3–4.mass could be secondary to a failure to thrive. To address
this, we explored the role of XOR in adipogenesis in vitro
and in relation to adipogenic factors.
XOR Expression Is Dependent on the Proadipogenic
Transcription Factor C/EBPb
To explore the determinants of XOR induction during
adipogenesis, we titrated the three components of the
induction cocktail: insulin, dexamethasone, and the
phosphodiesterase inhibitor IBMX. Increasing insulin and
dexamethasone concentrations minimally perturbed
XOR expression at 6 hr postinduction (Figure S3), whereas
increasing concentrations of IBMX proportionally in-
creased XOR gene expression (Figure 3A). Addition of
IBMX elevates the intracellular cyclic AMP concentration.
Because cAMP induces expression of the proadipogenic
transcription factor CCAAT/enhancer binding protein
b (C/EBPb), we considered the possible role of this factor
in regulating XOR expression in adipocytes.Cell MeComparison of microarray expression profiles for XOR
and C/EBPb showed a significant correlation (Figure 3B)
in the expression pattern of the two genes. To test whether
C/EBPb is necessary for induction of XOR during adipo-
genesis, 3T3-L1 preadipocytes were retrovirally trans-
fected with two C/EBPb siRNA constructs and assayed
for XOR expression from 6 hr postinduction onward.
XOR expression was significantly reduced in the two
knockdown cell lines relative to control hairpin (Figure 3C),
suggesting that XOR lies downstream of C/EPBb-depen-
dent pathways.
XOR Is Necessary for Adipogenesis In Vitro,
and Knockdown of XOR Inhibits Fat Accumulation
To examine the function of XOR in adipogenesis, short-
hairpin siRNA retroviral constructs targeting three regions
of the XOR mRNA were generated and stably transfected
into 3T3-L1 preadipocytes (Figure 4A). Cells expressing
control hairpins differentiated normally, and XORtabolism 5, 115–128, February 2007 ª2007 Elsevier Inc. 117
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Regulation of Adipogenesis by Xanthine OxidaseFigure 2. XO Expression and Activity Is Elevated in Obese Mice
(A) XOR expression was assayed in the white adipose tissue of 6- to 8-week-old WT, obese ob/obmice and in ob/obmice treated with leptin over a
12 day time period. N = 2–3.
(B) Serum uric-acid levels are elevated in ob/ob mice relative to WT and normalized by leptin treatment. N = 3.
(C) Body weights in 2-week-old male XOR / mice (N = 6) and WT littermates (N = 4).
(D) Analysis of adipose tissue content by NMR spectroscopy.
(E) Quantitation of serum-free fatty acids, glucose, and triglycerides. Data in all panels are presented as means ± SEM.expression was similar to that of untransfected 3T3-L1
cells. XOR expression was significantly reduced by 76%
in cell lines derived from construct 1 (XO-1), 53% from
construct 2 (XO-2), and 21% in construct 3 (XO-3)
(Figure 4A). A reduction in functional enzyme for construct
XO-1 was confirmed by HPLC analysis (Figure 4B). The
knockdown cell lines were then induced to differentiate,
and lipids were stained on day 7 using oil-red-O (Fig-
ure 4C). Cells were also assayed for mRNA expression
of aP2, a terminal marker of adipogenesis (Figure 4D). A
reduced lipid accumulation and aP2 expression was
observed for all three constructs, with knockdown XO-1
having the greatest effect. Overall, the efficiency of XOR
knockdown in these constructs correlated with the extent
of the inhibition of adipocyte differentiation. In addition,
expression of C/EBPa, PPARg, and SREBP1c mRNAs,
which normally increase during adipogenesis, was abro-118 Cell Metabolism 5, 115–128, February 2007 ª2007 Elseviergated in XOR-knockdown cells, whereas expression of
C/EBPb mRNA, a putative regulator of XOR, was unaf-
fected (Figure 4E).
XOR is a potent generator of reactive oxygen species
with the ability to generate oxidized LDL (oxLDL) in vitro.
OxLDL is a source of PPARg agonists and can induce
activation of PPARg in macrophages (Nagy et al., 1998;
Tontonoz et al., 1998). In addition, recent studies have
shown production of an endogenous activity during the
first 2 days of adipogenesis that activates PPARg (Tzameli
et al., 2004). This reported activation of PPARg is within
the time frame of maximal XOR expression. With this in
mind, wewondered if inhibition of XOR blocked adipogen-
esis by blocking PPARg activity or acted further upstream
of PPARg. To distinguish between these two possibilities,
the PPARg agonist rosiglitazone was added to control
hairpin and XOR-knockdown cells during adipogenesisInc.
Cell Metabolism
Regulation of Adipogenesis by Xanthine OxidaseFigure 3. C/EBPb Is Required for XOR Gene Expression
(A) 3T3-L1 cells were treated with increasing IBMX concentrations at induction of adipogenesis, and XOR expression was assayed at 6 hr postinduc-
tion. Data are presented as means ± SEM. N = 2.
(B) Microarray expression profiles as described in Figure 1were correlated to XOR (black line). Expression of C/EBPb (gray line) correlated to XORwith
Pearson correlation coefficient R2 = 0.93.
(C) Stable 3T3-L1 cell lines infected with C/EBPb siRNA constructs were assayed for XOR expression at 6 hr postinduction. XOR expression is sig-
nificantly reduced in the C/EBPb knockdown cell lines (cb-A, open square and cb-B, open triangle) relative to control hairpin (closed diamonds). Data
are presented as means ± SEM. N = 2.(Figure 4F). Rosiglitazone completely rescued adipogene-
sis in all three XOR-knockdown lines as assayed by oil-red
O staining, suggesting that XOR acts upstream of PPARg
and may be involved in the activation of the receptor
(Figure 4F).
XOR Is Necessary for PPARg Activity in 3T3-L1 Cells
PPARg is activated by a variety of compounds but the
identity of the endogenous ligand is unknown. Previous
studies have shown that activation of PPARg in 3T3-L1Cell Mcells depends on cAMP and C/EBPb (Hamm et al., 2001)
as well as SREBP1c (Kim et al., 1998) and that production
of an endogenous PPARg ligand (Tzameli et al., 2004) is
cAMP dependent. Similarly, XOR expression is induced
primarily by the cAMP-inducing agent IBMX and is depen-
dent on C/EBPb. This line of evidence led us to consider
a possible role for XOR in activating PPARg, either directly
or indirectly.
To test this hypohesis, XOR-knockdown constructs
were transfected into 3T3-L1 preadipocytes (5B2 cells)etabolism 5, 115–128, February 2007 ª2007 Elsevier Inc. 119
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Regulation of Adipogenesis by Xanthine OxidaseFigure 4. Knockdown of XOR by siRNA Inhibits Adipocyte Differentiation
(A) Retroviral constructs expressing short hairpin RNAs encoding three different XOR regions were used to infect 3T3-L1 preadipocytes. Efficacy of
XOR knockdown was tested after induction of differentiation. In control hairpin-expressing cells, XOR expression matches untransfected 3T3-L1. In
XOR-knockdown cell lines, XOR expression was significantly reduced in all three constructs. Efficiency of knockdown correlated with the distance
from the 50 end. Data are presented as means ± SEM. N = 2.
(B) XDH (black bar) and XO (white bar) activities are reduced by approximately 80% in XO-1 versus control hairpin cell lines as assayed by HPLC. Data
are presented as means ± SEM. N = 3.
(C) Lipid droplets were visualized by oil red O staining, at day 7, in the XOR-knockdown cells.
(D) aP2 expression is most significantly reduced in the XO-1 cells. Data are presented as means ± SEM. N = 2.
(E) C/EBPa, PPARg, SREBP1c, and C/EBPb-mRNA levels were measured in the control (white bar) and XO-1 cells (black bar). mRNA levels of all
genes are significantly decreased in the XO-1 cells except for C/EBPb. Statistical analysis was performed by Oneway Anova. Pairwise comparison
was done by Tukey-Kramer honestly significant difference (HSD). Data are presented as means ± SEM. N = 3. p < 0.01.
(F) Adipogenesis is restored in the XOR-knockdown cells by treatment with 1 mM rosiglitazone (R) from days 0–2 of induction. Cells were stained with
oil red O at day 7.120 Cell Metabolism 5, 115–128, February 2007 ª2007 Elsevier Inc.
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Regulation of Adipogenesis by Xanthine OxidaseFigure 5. XOR Is Necessary for PPARg Activity during Adipogenesis
(A) Schematic representation of the MSVg construct expressed in 5B2 cells.
(B) 5B2 cells were retrovirally infected with XOR-knockdown vectors and assayed for b-gal activity following induction with cocktail. XO-1 knockdown
significantly reduced b-gal activity.
(C) Conditionedmedia from XO-1 and control-hairpin knockdowns collected at day 2 after induction were organically extracted and tested for PPARg
activity on 5B2 cells. Labels are as follows: Cd2, organic extract from noninduced cells; CMd2, organic extract from cocktail-induced cells; Ctrl, or-
ganic extract from induced vector-infected cells; and XO-1, organic extract from knockdown-induced cells. Statistical analysis in (B) and (C) was
performed by Oneway Anova. Pairwise comparison was done by Tukey-Kramer HSD. Data are presented as means ± standard deviation (SD).
N = 3. p < 0.05.
(D) Organic extracts from vector and knockdown-induced cells were applied to vector and XO-1-infected 3T3-L1 preadipocytes. Cells were oil red O
stained at day 8.that express a PPARg ligand-monitoring b-galactosidase
(b-gal) reporter (MSVg). The MSVg construct encodes
both a Gal4-DNA binding domain fused to the PPARg li-
gand binding domain (LBD) as well as b-gal as a reporter,
on a single plasmid. Expression for both effector and
reporter is under the control of five Gal4 specific binding
sites (UAS5) and the hsp68 minimal promoter (Figure 5A).Cell MThe MSVg construct thus provides a readout of endoge-
nous PPARg activity (Tzameli et al., 2004).
Clonal 5B2 preadipocytes expressingMSVgwere retro-
virally infectedwith XOR-knockdown vectors and assayed
for b-gal activity following induction with differentiation
cocktail (DIM), relative to noninduced cells. Noninduced
cells were mock induced with maintenance media.etabolism 5, 115–128, February 2007 ª2007 Elsevier Inc. 121
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lines (Figure 5B) and reduction correlated with knockdown
efficiency (Figure 4A). At day 1, b-gal activity was reduced
by 66% in XO-1, 42% in XO-2, and 45% in XO-3
knockdowns.
Previously, the endogenous PPARg activity has been
shown to accumulate in the organic extract from condi-
tioned media of differentiating 3T3-L1 cells (Tzameli
et al., 2004). To assess if XOR regulates the production
of such a secreted component as well, media from XOR-
knockdown and control-cell lines were organically ex-
tracted. The organic extracts were tested for their ability
to activate PPARg and increase b-gal activity by addition
to the 5B2 reporter cells (Figure 5C). Organic extract col-
lected from day 2 differentiating 3T3-L1 cells (CMd2) but
not extract from noninduced cells (Cd2) increased activity
2.5-fold above baseline. Extracts from 3T3-L1 cells in-
fected with control hairpin vector produced a comparable
4-fold induction, while extracts from XO-1 cells were un-
able to increase b-gal activity. The same extracts were
also tested for adipogenesis and fat accumulation by sup-
plementing them to confluent preadipocytes (Figure 5D).
As shown, increased adipogenesis was observed by oil
red O staining when organic extracts from control hairpin
cells were added to vector-infected cells and XO-1 knock-
down cells. On the other hand, extracts from XO-1 knock-
down cells were defective in inducing lipid accumulation.
Together, these data suggest that XOR enzymatic path-
ways produce secreted components that activate PPARg
and promote adipogenesis.
Complex Effect of XOR Overexpression
on PPARg Activity and Adipogenesis
Given these results, we sought to determine if overexpres-
sion of XOR could enhance PPARg activation. A retroviral
construct encoding human XOR cDNA (hXOR) was used
to produce 3T3-L1 cells overexpressing hXOR. hXOR
cells showed increased expression of hXOR mRNA while
inhibiting induction of the endogenous mouse XOR
(Figure 6A). hXOR cells also showed a modest 2.5-fold
increased in functional enzyme activity as assayed by
HPLC (Figure S4).
Overexpression of XOR is implicated in an array of dis-
eases arising from tissue injury and endothelial dysfunc-
tion relating to increased ROS generation (Harrison,
2002; Pacher et al., 2006). In addition, exogenous xan-
thine oxidase is commonly used as a source of superoxide
in experimental models of oxidative damage. With this po-
tential complication inmind, we tested the effect of consti-
tutive hXOR overexpression on the ability of the cells to
accumulate fat. As shown, hXOR cells showed decreased
C/EBPa, PPARg, and aP2 mRNA expressions (Figure 6A)
and reduced fat accumulation (Figure 6B).
Despite the negative effect of XOR overexpression on
adipogenesis, there was still an increase in PPARg activa-
tion. Organically extracted conditioned media from vector
and hXOR cells, collected at the indicated days after
induction of adipogenesis, were tested for their ability to
activate PPARg and increase b-gal activity (Figure 6C).122 Cell Metabolism 5, 115–128, February 2007 ª2007 ElsevierAn enhanced PPARg activation was produced, which
was most prominent by hXOR extracts collected at day
4 after differentiation, relative to extracts from vector cells.
In addition, all XOR extracts were more potent than vector
extracts in inducing fat accumulation (Figure 6D).
We then evaluated the ability of XOR chemical inhibitors
to block PPARg activation and adipogenesis. For this,
noninfected and hXOR-infected 5B2 cells were assayed
for b-gal activity in the presence of oxypurinol. Oxypurinol,
the active form of the XOR-inhibitor allopurinol, was inef-
fective in inhibiting differentiation-dependent increases
in b-gal and therefore PPARg activity when added to pa-
rental (Figure 6E), vector-infected, or hXOR-5B2 cells (Fig-
ure 6F). In addition, either 50 or 100 mM oxypurinol were
unable to potently inhibit adipogenesis and lipid- droplet
formation (Figure 6G). Oxypurinol inhibits the oxidase
activity of XOR by binding to the molybdenum site of the
enzyme (Spector, 1988), but not its FAD site-dependent
dehydrogenase (NADH-oxidizing) activity (Zhang et al.,
1998). Given that XOR exists in 3T3-L1 cells mainly as
a dehydrogenase (Figure 1D), we sought to find alternative
inhibitors. Several reports (Doussiere and Vignais, 1992;
Sanders et al., 1997; Zhang et al., 1998) have suggested
that diphenyleneiodonium (DPI), a powerful inhibitor of
the FAD site of XOR, blocks XOR-mediated reactive
oxygen species (ROS) generation from NADH oxidation.
Although an inhibitor not exclusive to XOR, we tested
DPI in adipogenic and PPARg activity assays. DPI was
able to inhibit PPARg activity in parental (Figure 6E), vec-
tor, and hXOR-overexpressing 5B2 cells (Figure 6F) as
well as fat accumulation (Figure 6G). This result suggests
that the NADH-oxidizing activity of XOR may be involved
in the activation of PPARg.
Finally, in 5B2 cells overexpressing hXOR, b-gal activity
was significantly increased following induction with differ-
entiation cocktail (DIM) (Figure 7A). This increase was up
to 150% relative to the control vector cell line and re-
mained elevated nearly 2-fold above baseline through
day 6 postinduction. Interestingly, a 2-fold increase of
b-gal activity was also observed in 5B2 preadipocytes
that did not receive induction cocktail (Figure 7A). In cells
treated with 1 mM rosiglitazone for a maximum of 2 days,
b-gal activity was increased 5-fold by day 1 and remained
elevated to over 7-fold until day 6. The observed potenti-
ation of the rosiglitazone-dependent activation of the re-
porter system was intriguing, so we sought to analyze it
more extensively. For this, we evaluated increases in
b-gal activity at day 1, in cells stably expressing hXOR
and with concentrations of rosiglitazone ranging from
100 nM to 1 mM. Again, overexpression of hXOR resulted
in a 2-fold increase in b-gal activity over that of the vector
cells, observed at all concentrations of the agonist (Fig-
ure 7B). These results indicate that hXOR enzymatic
pathways affect the ligand-dependent transactivation of
PPARg.
In an effort to understand how hXOR affect the ligand-
dependent transactivation of PPARg, we investigated
possible XOR-induced changes in the ligand binding do-
main (LBD) of PPAR~g . We performed a trypsin-digestionInc.
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Regulation of Adipogenesis by Xanthine OxidaseFigure 6. XOR Overexpression Increases PPARg Activity but Inhibits Adipogenesis
(A) 3T3-L1 cells stably expressing control vector (white bar) or hXOR (black bar) were induced to differentiate. RNA collected at day 0, 1, and 5 after
induction was used to assay the levels of hXOR, endogenous mouse XOR, C/EBPa, PPARg, and aP2.
(B) Vector and hXOR-infected 3T3-L1 cells were induced to differentiate. Cells were stained with oil red O at day 8. Statistical analysis was performed
by Oneway Anova. Pairwise comparison was done by Tukey-Kramer HSD. Data are presented as means ± SEM. N = 3. p < 0.01.
(C) Conditioned media from vector and hXOR 3T3-L1 cells were collected at day 0, 1, 2, and 4 after adipogenesis and were organically extracted. 5B2
cells were then incubated with these extracts for 24 hr before assayed for b-gal activity.
(D) Organic extracts as described in 6C were applied to 3T3-L1 preadipocytes and assayed for fat accumulation by oil red O staining.
(E) 5B2 cells induced to differentiate with cocktail (DIM) were also treated with 100 mM of oxypurinol (Oxy), 10mM of DPI, 1 mM rosiglitazone, and their
combinations. Twenty four hours later, cells were lysed and assayed for b-gal activity. Statistical analysis in (C), (E), and (F) was performed by Oneway
Anova. Pairwise comparison was done by Tukey-Kramer HSD. Data are presented as means ± SD. N = 3. p < 0.05.
(F) Vector-infected 5B2 cells (white bar) and hXOR-overexpressing 5B2 cells (black bar) were induced to differentiate as in 5C before they were as-
sayed for b-gal activity.
(G) 3T3-L1cellswere induced todifferentiate by the standard cocktail in the absenceorpresenceofDPI or oxypurinol. Twenty-four-hour treatmentwith
DPI blocked fat accumulation. Twenty-four-hour treatment with oxypurinol did not inhibit fat accumulation significantly. Cells were stained at day 8.Cell Metabolism 5, 115–128, February 2007 ª2007 Elsevier Inc. 123
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Regulation of Adipogenesis by Xanthine OxidaseFigure 7. XOR Potentiates Activation of PPARg by Rosiglitazone and Promotes Fat Accumulation in NIH-3T3
(A) b-Gal activity was measured in vector- and hXOR-overexpressing 5B2 cells at day 1, 2, 4, and 6 postinduction. Labels are as follows: None, no
cocktail; DIM, cocktail; Rosi, 1 mM rosiglitazone from days 0–2.
(B) b-Gal activity was measured at day 1, in vector- and hXOR-overexpressing 5B2 cells treated with DIM or increasing amounts of rosiglitazone.
Statistical analysis in (A) and (B) was performed by Oneway Anova. Pairwise comparison was done by Tukey-Kramer HSD. Data are presented as
means ± SD. N = 3. p < 0.05.
(C) 35-S-labeledPPARgwas incubatedwithsolvent (), 1mMrosiglitazone (R), or increasingamountsoforganic extracts from3T3-L1 (CM), hXORandXO-1
cells for 30min. The reactionswere treatedwith trypsin for 7 min and analyzed on a 15%SDS gel. The gel was dried and exposed to film for visualization.
(D) NIH-3T3 cells stably expressing PPARg2 were induced to differentiate with 1 mM rosiglitazone (R), standard cocktail (DIM)/+R, XO-1 extracts/+R,
and hXOR extracts/+R from day 0–2. Lipids were visualized 12 days later.124 Cell Metabolism 5, 115–128, February 2007 ª2007 Elsevier Inc.
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extracts from parental 3T3-L1 cells, XOR-knockdown
and XOR-overexpressing cells. In this assay, ligand bind-
ing as well as coactivator or corepressor binding results in
stabilization of the LBD and increased resistance to diges-
tion by proteases (Pissios et al., 2000). As shown, extracts
from XOR-overexpressing cells protected PPARg from
degradation, whereas extracts from knockdown cells did
not (Figure 7C), suggesting that XOR extracts have an ef-
fect on the stabilization of the PPARg LBD.
We then attempted to further investigate the ability of
the extracts from knockdown and overexpressing cells
to activate PPARg and, as a consequence, the adipogenic
program, in a cell system related to but distinct from 3T3-
L1 cells. For this, we infected NIH-3T3 fibroblasts with
a PPARg2-expressing virus and established an NIH-g2
cell line that we induced to differentiate in response to
XOR extracts. As shown in Figure 7D, differentiation cock-
tail (DIM) and extracts from XOR-overexpressing cells
induced fat accumulation in theNIH-g2cells to a compara-
ble degree, whereas extracts from XO-1 knockdown cells
did not. Rosiglitazone treatment resulted in efficient fat ac-
cumulation, and it rescued the adipogenic defect of the
XO-1-treated cells. Finally, addition of rosiglitazone to
the hXOR extracts resulted in enhanced fat accumulation
compared to that achieved by the rosiglitazone + DIM
combination. This result suggests that the XOR enzymatic
activity produces extractable components with the ability
to activate PPARg in a heterologous system.
DISCUSSION
A better understanding of the full complement of factors
required for normal adipogenesis could form the basis
for new therapies that directly target the development of
adipose tissue mass. Toward this end we employed
a novel computational strategy to identify gene products
that might play a role in the early phases of adipogenesis.
In this report, we used this algorithm to identify XOR as a
novel regulator of adipogenesis and fat accretion and
present additional evidence implicating XOR in the regula-
tion of PPARg activity.
XOR is the principal enzyme responsible for oxidation of
purine metabolites to uric acid. Hyperuricemia is highly
correlated with increased adiposity, obesity, and the met-
abolic syndrome (Berry and Hare, 2004; Harrison, 2002;
Pacher et al., 2006). Serum leptin is also positively associ-
ated with uric-acid levels in humans (Fruehwald-Schultes
et al., 1999), while weight loss is associated with de-
creased urate levels and lowered risk of gout, a disease
of urate-crystal deposition (Choi et al., 2005). Our results
demonstrate that XOR is highly expressed in adipose tis-
sue compared to other tissues (Figure 1B) and that XOR
expression, enzymatic activity, and its product urate are
all elevated in obese states (Figure 2). Therefore, adipo-
cyte-derived XOR activity may play a direct role in the hy-
peruricemia associated with obesity.
XOR is necessary for adipogenesis in vitro and analyses
of XOR knockout mice suggests that it could also playCell Ma role in this process in vivo. To date, two groups have in-
dependently described the phenotype of XOR null mice
(Ohtsubo et al., 2004; Vorbach et al., 2002). Although
both mouse models carry a global deletion of XOR and
die perinatally, the two knockout strains have distinct
differences in lactation. The mice used in this study lack
lactation defects and instead die because of renal displa-
sia (Ohtsubo et al., 2004). Nonetheless, prior to their de-
mise, the XOR-knockout mice show significant reduction
in adipose stores versus WT mice, at 2 weeks of age (Fig-
ures 2C–2E). Because XOR is significantly induced during
in vitro adipogenesis, and siRNA-mediated reduction
of XOR inhibits adipocyte differentiation and PPARg-
mediated gene expression (Figure 4), we suggest that
XOR deficiency in adipose tissue could be a contributing
factor to the perinatal lethality seen in these mice. In
contrast to mice, humans with XOR deficiency can be
asymptomatic or present with xanthinuria, leading to xan-
thine calculi in urine and renal failure (Ichida et al., 1997;
Levartovsky et al., 2000). The basis for this species differ-
ence is not known.
Adipogenesis is characterized by the successive activa-
tion of transcriptional factors and their downstream gene
targets, resulting in lipid accumulation (Spiegelman and
Flier, 2001). These factors, which include C/EBPb, C/
EBPd, Klf5, and Krox20, among others, ultimately induce
activation of PPARg (Chen et al., 2005; Lane et al., 1999;
Oishi et al., 2005). Among them, C/EBPb is expressed
very early following induction of 3T3-L1 preadipocytes,
and ectopic expression of C/EBPb in multipotent NIH-
3T3 cells induces PPARg and fat accumulation (Wu
et al., 1995). In addition, loss-of-function studies demon-
strate the requirement of this transcription factor for adi-
pogenesis in vitro and in vivo (Chen et al., 2005; Tanaka
et al., 1997). Interestingly, overexpression of C/EBPb in
neuronal cells was shown to elevate XOR expression
(Cortes-Canteli et al., 2004), and functional C/EBPb bind-
ing sites were recently reported to exist on the rat XOR
promoter (Chow et al., 1995). C/EBPb was also found to
activate themouse XORpromoter inmousemammary ep-
ithelial cells (Seymour et al., 2006). Our results now show
that C/EBPb may also play a role in the regulation of XOR
in adipocytes since C/EBPb knockdown in 3T3-L1 cells
results in reduced XOR mRNA (Figure 3C). On the other
hand, C/EBPb-mRNA levels remain unaffected in XOR-
knockdown cells (Figure 4E). In aggregate, our findings
suggest that XOR may be a downstream target of C/
EBPb and a mediator of C/EBPb actions in adipogenesis.
While there have been successful efforts to identify the
transcription factors that induce expression of PPARg,
much less is known about factors that affect the ligand-
dependent activity of the receptor. The evidence in this
report indicates that XOR may serve this function. A
knockdown of XOR in 3T3-L1 preadipocytes renders
them defective in inducing markers of terminal differentia-
tion such as C/EBPa, PPARg, SREBP1c, and aP2 (Fig-
ure 4E) and in accumulating fat (Figure 4F), suggesting
that XOR plays a pivotal role during the early event
of the process. Adipogenesis is fully restored in theetabolism 5, 115–128, February 2007 ª2007 Elsevier Inc. 125
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ure 4F), suggesting that this blockage is upstream or at
the level of PPARg activation. An assay able to monitor
PPARg activity in 3T3-L1 cells shows that XOR-knock-
down blocks differentiation-dependent PPARg activation
(Figure 5B) and suggests that XOR may be required for
the activation of PPARg. In addition, chemical inhibition
of the dehydrogenase activity of the enzyme (Figures 6E
and 6F) reduces PPARg activation, inhibits adipogenesis
(Figure 6G), and implicates the NADH-oxidizing activity
of XOR and the concomitant generation of ROS in activat-
ing PPARg (Zhang et al., 1998). Overexpression of the
enzyme in 3T3-L1 cells increases the b-gal activity of the
reporter system even in undifferentiated preadipocytes
(Figure 6C) and causes a significant increase in the
amount and duration of those secreted components that
activate PPARg and promote adipogenesis (Figure 6D).
Finally, a trypsin-digestion assay shows enhanced stabili-
zation of the PPARg LBD in the presence of extracts from
XOR-overexpressing cells, adding further evidence to the
conclusion that XOR can stimulate the synthesis of PPARg
ligands and/or cofactors (Figure 7C). This line of evidence
initially suggested that XOR might be involved in the syn-
thesis of the elusive PPARg ligand. For example, XOR is
able to oxidize LDL, and such oxLDL particles have
been reported to contain PPARg-ligand-type activities
(Nagy et al., 1998; Tontonoz et al., 1998). The observation
though that XOR overexpression strongly potentiates the
rosiglitazone-dependent activation of PPARg (Figures 7A
and 7B) suggests that the mechanism by which XOR af-
fects PPARg may be more complex. While the precise
mechanism by which XOR increases PPARg activity is
not known, the data suggest that the following mecha-
nisms may contribute: (1) promoting the generation of
another endogenous ligand with unique properties, (2)
modifying and turning weaker endogenous ligands into
high-affinity ones, or (3) promoting changes in the recep-
tor LBD that stabilize binding of endogenous as well as
exogenous ligands. Additional experiments are required
to clarify this point.
It is also intriguing that the increase in PPARg activity is
not associated with increased adipogenesis in the XOR-
overexpressing cells (Figure 6B). As shown here, XOR
expression and activity are tightly regulated, with a robust
increase during the first 24 hr after initiation of differentia-
tion and then a return to basal levels. It is therefore possi-
ble that prolonged presence of XOR, as is often the case
for tightly regulated factors expressed outside their natu-
ral time window, inhibits adipogenesis.
In summary, we report here that XOR is a novel regulator
of adipogenesis and PPARg activity. Inhibition of its ex-
pression and/or enzymatic activity blocks both PPARg ac-
tivation and fat accumulation. To our knowledge, there
have not been studies designed to explore the effects of
XOR inhibitors on body weight, and in light of our findings,
such studies may be warranted. Our observations impli-
cate XOR as a regulator of nuclear-hormone receptor
activity and identify XOR as a potential therapeutic target
for metabolic abnormalities beyond hyperuricemia.126 Cell Metabolism 5, 115–128, February 2007 ª2007 ElsevierEXPERIMENTAL PROCEDURES
Materials
Methylisobutylxanthine (MIX), insulin, dexamethasone, oil red O, and
oxypurinol were fromSigma-Aldrich (St. Louis, MO). The Galacto-Light
kit was from Tropix (Foster City, CA), charcoal-dextran stripped serum
fromHyclone (Logan, UT), and diphenyleneiodonium and rosiglitazone
from Cayman Chemicals.
Microarray Analysis
Microarray data for 3T3-L1 adipogenesis (from Soukas et al., 2001)
were analyzed using a novel algorithm. Let g(t) be defined as transcrip-
tion of a single gene over time. Each gene expression profile g(t) can be
expressed as a linear combination of n sigmoidal functions fi(t) from i =
1 to n. Best fit parameters were derived from nonlinear regression us-
ing SigmaPlot for each g(t). Given the dimensionality of the data set (10
time points), nwas set at 2. Genes were then ranked by goodness of fit
as related to their R2 values (see Figure S1) with highest R2 values
ranked first.
Retroviral Plasmids and Infections
For knockdown of XOR, we used DNA-based retroviral vector-
mediated siRNA technology (Clontech’s RNAi-Ready pSIREN-RetroQ
system). Targeted sequences were determined by the Whitehead
Institute siRNA-designing tool, and specificity was verified by BLAST
analysis. Two complementary oligos for each targeted sequence
were ligated into the BamHI/EcoRI-linearized pSIREN-RetroQ Vector.
Sequences for the antisense oligonucleotides are as follows: XO-1
(positions 2–24) GGTAGACCAGAAGTGTTGT, XO-2 (positions 626–
648) CCTGGATCCAGGTCACACG, and XO-3 (positions 3053–3075)
CCATCTTGGTGTGAAGGCC.
For overexpression studies, a pcDNA3.1-myc-hisA() human-XOR
construct (kindly provided by Dr. Toren Finkel) was subcloned into
the retroviral pMSCV-hygromycin vector (Clontech). The hXOR gene
was excised with 30 myc and His tags included using NheI and AflII re-
striction sites, blunt ended, dephosphorylated, and ligated into HpaI
cut MSCV-hygro backbone. Plasmids were verified by sequencing.
Recombinant pMSCV or pSIREN-RetroQ viral packaging was
achieved by transfection of the plasmids into Phoenix ecotropic pack-
aging cells using Lipofectamine 2000 (Invitrogen). Viral supernatants
supplemented with 8 mg/ml polybrene were used to infect 3T3-L1,
5B2, or NIH-3T3 cells for 24–36 hr. Cells were than selected with
2 mg/ml puromycin or 100 mg/ml hygromycin (Sigma).
Infected 5B2 cells were induced to differentiate, and b-gal activity
was measured at different time points. Similarly, infected 3T3-L1 and
NIH-3T3 cells were induced to differentiate following standard proto-
cols and assayed for lipid content.
Adipocyte Differentiation Assays
3T3-L1 cells (ATCC, Manassas, VA) were maintained in DMEM with
10% FBS (Invitrogen) in 5%CO2. Stable cell lines from retroviral trans-
duction were cultured to confluence and exposed to the differentiation
cocktail (1 mg/ml insulin, 0.25 mg/ml dexamethasone, and 0.5 mM
IBMX). Forty-eight hours later, cells were switched to medium contain-
ing 1 mg/ml insulin until day 7 for harvest. oil red O staining was de-
scribed previously (Soukas et al., 2001).
Total RNA Extraction and Quantitative RT-PCR
Total RNA was isolated from cells by TRIZOL reagent (Invitrogen).
Quantitative RT-PCR was performed by the Taqman system (Applied
Biosystems) according to manufacturer’s instructions. Oligos were
designed by the PrimerExpress software. Threshold cycles (Ct) for
the internal control (cyclophilin) and target genes were determined
from raw fluorescence. For Figures 4E and 6A, RNA from 3T3-L1 cells
was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) and
DNase I treated (Qiagen), according to the manufacturer’s instruc-
tions. mRNAs were quantitatively measured using a Stratagene MX
4000 Multiplex Quantitative PCR system and single- step quantitativeInc.
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Regulation of Adipogenesis by Xanthine OxidaseRT-PCR kit (Stratagene, Cedar Creek, TX). Total RNA was diluted in
the range of 0.1–100 ng and used to establish standard curves for
each individual gene. Normalization of each mRNA was done by the
corresponding TBP mRNA measurement.
XOR Activity and Uric-Acid Assays
Cell lysates were suspended in 50 mM potassium phosphate buffer
(pH 7.8) with EDTA and 1X complete protease mini tablet, sonicated,
and filtered using a YM-30 centricon filtration device. For the HPLC
assays, samples were mixed 1:1 with appropriate 2X buffers for final
concentration of 100 mM xanthine + NAD (to assay XDH + XO activity,
otherwise XO activity) and also with pyruvate, LDH, and DTE. Samples
were then incubated at 37C for 2–4 hr and acid precipitated with 1%
perchloric-acid final concentration. HPLC analysis was done by an
HPLC HP1040 system, using a C18 120A DENALI column (Vydac)
and isocratic elution with sodium phosphate buffer/1% acetonitrile
pH 2.5, with UV detection at A290 nM. Sample absorbance area under
the curve was calculated and normalized to UA standard, incubation
time, and protein concentration as assayed by Bradford assay. For
uric-acid assays, plasma samples from WT, ob/ob, and leptin-treated
ob/ob mice were assayed using a uric-acid SL kit from Diagnostic
Chemicals (Oxford, CT).
XOR Knockout Mice Body Composition and Serum Chemistries
Animal care and experimental procedures were performed with
approval from the Animal Care and Use Committee of NHLBI under
established guidelines. XOR / mice were genotyped as described
(Ohtsubo et al., 2004). For body composition measurements,
15-day-oldmale pupswere analyzed using a tabletop Bruker Minispec
NMR Analyzer mq10 that detects the amount of fat, muscle, and free
fluid in nonanesthetized mice. The mice were then anesthetized
for blood collection and serum chemistry analysis. The mice were
euthanized and the fat pads dissected for quantitation and histological
analysis. The fat tissues were fixed on formalin, embedded on paraffin,
and mounted on slides for Hematoxylin and Eosin staining (Histoserv,
Gaithersburg, MD). Statistical analysis of samples was performed with
the two-sample student’s t test.
Organic Phase Extraction and Trypsin-Digestion Assay
Conditioned media from 3T3-L1 cells collected at different time points
after induction were acidified with 0.1 N HCl, mixed with ethyl
acetate:acetone (1:1, v/v), and centrifuged at 1000xg for 5min. The up-
per phase was transferred to a new tube, washed twice with NaCl, and
evaporated. Dried extracts were reconstituted in DMEM containing
10% stripped-serum FBS and used to treat cells as described previ-
ously (Tzameli et al., 2004).
For the protease digestion assay, 2 ml of in vitro translated
35S-labeled PPAR was incubated with EtOH, 1 mM rosiglitazone, or
increasing amounts of organic extracts from noninfected differen-
tiating, hXOR-overexpressing, and XO-1-knockdown cells. After a
30 min incubation, 250 ng of trypsin was added to the reaction mixture
and protein was digestion at room temperature for 7 min. Reactions
were analyzed on a 15% SDS gel, after which the gel was dried and
exposed to film (Pissios et al., 2000).
Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://www.cellmetabolism.org/cgi/
content/full/5/2/115/DC1/.
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